arrow
T

Tuğçe Eşkazan

Istanbul University-Cerrahpasa
H指数:9
被引数:275

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Upadacitinib as a rescue therapy for steroid- and infliximab-refractory acute severe ulcerative colitis: short- and long-term effectiveness and safety in a multicenter cohort study

乌帕替尼作为对糖皮质激素和英夫利昔单抗难治的急性重度溃疡性结肠炎的救援疗法:一项多中心队列研究中的短期和长期有效性与安全性

2026-07-220
OAAI
Upadacitinib Rescue in Steroid- and Infliximab-Refractory Acute Severe Ulcerative Colitis: Remission in Half of Patients at 1 Year

乌帕替尼对糖皮质激素和英夫利昔单抗难治性急性重度溃疡性结肠炎的挽救治疗:1年时半数患者缓解

2026-01-010
PRE
Isolated vs Crohn's Disease-Related Complex Perianal Fistulas: Similar Profiles but Challenging Fistula Phenotype with Delayed Radiological Healing in Isolated Disease

孤立性 vs 克罗恩病相关复杂性肛周瘘管:相似特征但孤立性疾病的瘘管表型具有延迟性放射学愈合的挑战

2026-01-010
PRE
Intravenous versus Subcutaneous Infliximab in Perianal Fistulizing Crohn's Disease: A Two-Centre Real-World Comparison of Clinical, Endoscopic and Radiologic Outcomes

静脉注射与皮下注射英夫利昔单抗治疗肛周瘘管型克罗恩病:一项比较临床、内镜和放射学结局的两中心真实世界研究

2026-01-010
PRE
Comparison of Azathioprine-Induced Pancreatitis and Gastrointestinal Intolerance in IBD: Role of Demographics, Clinical Variables, and HLA DQA1/DRB1 Alleles

比较硫唑嘌呤诱导的胰腺炎与胃肠道不耐受在炎症性肠病中的差异:人口统计学、临床变量及HLA DQA1/DRB1等位基因的作用

2025-12-020
OAAI
Psychological and Clinical Factors Mediate Post-COVID-19 Irritable Bowel Syndrome

心理和临床因素介导后COVID-19肠易激综合征

2025-05-150
OAAI
Long-Term Impact of COVID-19 on Disorders of Gut-Brain Interaction: Incidence, Symptom Burden, and Psychological Comorbidities
2025-03-211
OAAI
Upadacitinib as a Rescue Therapy in Patients with Steroid- and Infliximab-Refractory Acute Severe Ulcerative Colitis: Real-Life Multicentre Results
2025-01-220
PRE